SAN DIEGO--(BUSINESS WIRE)--Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, announced today that it has released reagents designed for research use only studies analyzing CYP2C9 and VKORC1, two genes with potential applications in drug metabolism and response. The company plans to submit similar reagents, along with others, for FDA clearance in 2007.
